Irreversible Electroporation for Prostate Cancer

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Jun 2

PMID 34071934

Citations 9

Authors

Sean Ong

Matthew Leonardo

Thilakavathi Chengodu

Dominic Bagguley

Nathan Lawrentschuk

Affiliations

Soon will be listed here.

Abstract

Although it can be lethal in its advanced stage, prostate cancer can be effectively treated when it is localised. Traditionally, radical prostatectomy (RP) or radiotherapy (RT) were used to treat all men with localised prostate cancer; however, this has significant risks of post-treatment side effects. Focal therapy has emerged as a potential form of treatment that can achieve similar oncological outcomes to radical treatment while preserving functional outcomes and decreasing rates of adverse effects. Irreversible electroporation (IRE) is one such form of focal therapy which utilises pulsatile electrical currents to ablate tissue. This modality of treatment is still in an early research phase, with studies showing that IRE is a safe procedure that can offer good short-term oncological outcomes whilst carrying a lower risk of poor functional outcomes. We believe that based on these results, future well-designed clinical trials are warranted to truly assess its efficacy in treating men with localised prostate cancer.

Citing Articles

Investigation of the Bystander Effect on Cell Viability After Application of Combined Electroporation-Based Methods.

Barauskaite-Sarkiniene N, Novickij V, Satkauskas S, Ruzgys P Int J Mol Sci. 2025; 26(5).

PMID: 40076917 PMC: 11900407. DOI: 10.3390/ijms26052297.

Photodynamic therapy for the precise treatment of localized prostate cancer.

Xu Y, Tan Q, Sun C, Jia Y, Li S, Yang X Front Oncol. 2025; 15:1454392.

PMID: 39975598 PMC: 11835664. DOI: 10.3389/fonc.2025.1454392.

Rectourethral fistula following focal irreversible electroporation for prostate cancer.

Ong S, Alhamdani Z, Lawrentschuk N BMJ Case Rep. 2025; 15(9).

PMID: 39901390 PMC: 9445791. DOI: 10.1136/bcr-2022-249816.

High-Intensity Focused Ultrasound Ablation for Primary or Salvage Prostate Cancer Therapy: Initial Outcomes in the Veteran Healthcare Setting.

Patel S, Antar A, Alrabaa A, Saffati G, Fleming B, Srikishen N Life (Basel). 2025; 15(1).

PMID: 39859958 PMC: 11766662. DOI: 10.3390/life15010017.

Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE).

Diven M, Ballman K, Marciscano A, Barbieri C, Piscopo J, Wang S BMC Urol. 2024; 24(1):151.

PMID: 39054460 PMC: 11271032. DOI: 10.1186/s12894-024-01506-8.

References

Collettini F, Enders J, Stephan C, Fischer T, Baur A, Penzkofer T . Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. Radiology. 2019; 292(1):250-257. DOI: 10.1148/radiol.2019181987. View

Dong S, Wang H, Zhao Y, Sun Y, Yao C . First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer. Technol Cancer Res Treat. 2018; 17:1533033818789692. PMC: 6071159. DOI: 10.1177/1533033818789692. View

Valerio M, Ahmed H, Emberton M . Focal Therapy of Prostate Cancer Using Irreversible Electroporation. Tech Vasc Interv Radiol. 2015; 18(3):147-52. DOI: 10.1053/j.tvir.2015.06.005. View

Blazevski A, Scheltema M, Amin A, Thompson J, Lawrentschuk N, Stricker P . Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. 2019; 125(3):369-378. DOI: 10.1111/bju.14951. View

Valerio M, Stricker P, Ahmed H, Dickinson L, Ponsky L, Shnier R . Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2014; 17(4):343-7. PMC: 4227889. DOI: 10.1038/pcan.2014.33. View

Donati O, Jung S, Vargas H, Gultekin D, Zheng J, Moskowitz C . Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?. Radiology. 2013; 268(2):440-50. PMC: 6940013. DOI: 10.1148/radiol.13122149. View

Scheltema M, van den Bos W, Siriwardana A, Kalsbeek A, Thompson J, Ting F . Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int. 2017; 120 Suppl 3:51-58. DOI: 10.1111/bju.13991. View

Ong X, Bagguley D, Yaxley J, Azad A, Murphy D, Lawrentschuk N . Understanding the diagnosis of prostate cancer. Med J Aust. 2020; 213(9):424-429. DOI: 10.5694/mja2.50820. View

van den Bos W, Scheltema M, Siriwardana A, Kalsbeek A, Thompson J, Ting F . Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int. 2017; 121(5):716-724. DOI: 10.1111/bju.13983. View

10.

Ting F, Tran M, Bohm M, Siriwardana A, van Leeuwen P, Haynes A . Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis. 2015; 19(1):46-52. DOI: 10.1038/pcan.2015.47. View

11.

Ting F, van Leeuwen P, Stricker P . Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide. J Vasc Interv Radiol. 2016; 27(4):568. DOI: 10.1016/j.jvir.2016.01.003. View

12.

Blazevski A, Amin A, Scheltema M, Balakrishnan A, Haynes A, Barreto D . Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World J Urol. 2020; 39(4):1107-1114. DOI: 10.1007/s00345-020-03275-z. View

13.

Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B . Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. PLoS One. 2019; 14(4):e0215093. PMC: 6464181. DOI: 10.1371/journal.pone.0215093. View

14.

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

15.

Muller B, van den Bos W, Brausi M, Futterer J, Ghai S, Pinto P . Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol. 2015; 33(10):1503-9. PMC: 7721864. DOI: 10.1007/s00345-014-1475-2. View

16.

Wu L, Xu J, Gu H, Hua J, Zhu J, Chen J . Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol). 2013; 25(4):252-64. DOI: 10.1016/j.clon.2012.11.010. View

17.

Scheltema M, Chang J, van den Bos W, Bohm M, Delprado W, Gielchinsky I . Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. Eur Urol Focus. 2017; 5(4):585-591. DOI: 10.1016/j.euf.2017.10.007. View

18.

Edd J, Horowitz L, Davalos R, Mir L, Rubinsky B . In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng. 2006; 53(7):1409-15. DOI: 10.1109/TBME.2006.873745. View

19.

Murray K, Ehdaie B, Musser J, Mashni J, Srimathveeravalli G, Durack J . Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer. J Urol. 2016; 196(3):883-90. PMC: 5102502. DOI: 10.1016/j.juro.2016.02.2986. View

20.

Davalos R, Mir I, Rubinsky B . Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005; 33(2):223-31. DOI: 10.1007/s10439-005-8981-8. View